Optellum: Funding, Investors & Team (Sep 2026)

Optellum develops an imaging biomarker for smart lung cancer detection. Optellum’s vision is to redefine cancer care, by enabling every clinician, in every hospital, to manage their patients in the optimal way. They do that by providing end-end IT platform for personalized early diagnosis and therapy, based on the collective experience of thousands of doctors pooled by machine learning applied to vast patient datasets. Their first suite of products targets management of patients at high risk of developing lung cancer – the world’s deadliest and commonest cancer – from early diagnosis through to treatment. Optellum comprises a team of award-winning medical imaging software, AI, and clinical experts who met at Oxford’s world-renowned computer vision lab. Between us, they have track records of bringing innovation to market through over 10 start-up companies, resulting already in 5 trade-sales and one IPO. They are backed by an Advisory Board comprising world-leading clinicians and experts in deep learning ; and Oxford's most prominent investors. They are building up their product development team – join their fight against cancer, working together with former software engineers from top technology companies (Amazon, Facebook, Redhat) and veterans of medical imaging startups (e.g. Mirada Solutions – acquired by Siemens).

Optellum has raised $14.0M across 1 round on record. The most recent is a Series A of $14.0M announced in Sep 2022.

Optellum's most recent funding round on record is a Series A of $14.0M, announced in Sep 2022.

Jason Pesterfield is listed as CEO at Optellum.

Optellum is based in Oxford, Oxfordshire, United Kingdom.

Optellum is in the 11-50 employee band.

Optellum's latest round of $14.0M is above the $5.8M median round size for Artificial Intelligence companies on FundedIQ across 7,234 tracked companies over the last two years.